BACKGROUND: Pooling strategies have been used to reduce the costs of polymerase chain reaction-based screening for acute HIV infection in populations in which the prevalence of acute infection is low (less than 1%). Only limited research has been done for conditions in which the prevalence of screening positivity is higher (greater than 1%). METHODS AND RESULTS: We present data on a variety of pooling strategies that incorporate the use of polymerase chain reaction-based quantitative measures to monitor for virologic failure among HIV-infected patients receiving antiretroviral therapy. For a prevalence of virologic failure between 1% and 25%, we demonstrate relative efficiency and accuracy of various strategies. These results could be used to choose the best strategy based on the requirements of individual laboratory and clinical settings such as required turnaround time of results and availability of resources. CONCLUSIONS: Virologic monitoring during antiretroviral therapy is not currently being performed in many resource-constrained settings largely because of costs. The presented pooling strategies may be used to significantly reduce the cost compared with individual testing, make such monitoring feasible, and limit the development and transmission of HIV drug resistance in resource-constrained settings. They may also be used to design efficient pooling strategies for other settings with quantitative screening measures.
BACKGROUND: Pooling strategies have been used to reduce the costs of polymerase chain reaction-based screening for acute HIV infection in populations in which the prevalence of acute infection is low (less than 1%). Only limited research has been done for conditions in which the prevalence of screening positivity is higher (greater than 1%). METHODS AND RESULTS: We present data on a variety of pooling strategies that incorporate the use of polymerase chain reaction-based quantitative measures to monitor for virologic failure among HIV-infectedpatients receiving antiretroviral therapy. For a prevalence of virologic failure between 1% and 25%, we demonstrate relative efficiency and accuracy of various strategies. These results could be used to choose the best strategy based on the requirements of individual laboratory and clinical settings such as required turnaround time of results and availability of resources. CONCLUSIONS: Virologic monitoring during antiretroviral therapy is not currently being performed in many resource-constrained settings largely because of costs. The presented pooling strategies may be used to significantly reduce the cost compared with individual testing, make such monitoring feasible, and limit the development and transmission of HIV drug resistance in resource-constrained settings. They may also be used to design efficient pooling strategies for other settings with quantitative screening measures.
Authors: J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica Journal: Lancet Date: 1999-06-26 Impact factor: 79.321
Authors: P Richard Harrigan; Robert S Hogg; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Justin Woodward; Chanson J Brumme; Zabrina L Brumme; Theresa Mo; Chris S Alexander; Julio S G Montaner Journal: J Infect Dis Date: 2004-12-22 Impact factor: 5.226
Authors: J M Raboud; E Seminari; S L Rae; P R Harrigan; R S Hogg; B Conway; C Sherlock; M T Schechter; M V O'Shaughnessy; J S Montaner Journal: J Clin Microbiol Date: 1998-11 Impact factor: 5.948
Authors: R H Haubrich; S J Little; J S Currier; D N Forthal; C A Kemper; G N Beall; D Johnson; M P Dubé; J Y Hwang; J A McCutchan Journal: AIDS Date: 1999-06-18 Impact factor: 4.177
Authors: Michael P Busch; Simone A Glynn; Susan L Stramer; D Michael Strong; Sally Caglioti; David J Wright; Brandee Pappalardo; Steven H Kleinman Journal: Transfusion Date: 2005-02 Impact factor: 3.157
Authors: J M Raboud; S Rae; R S Hogg; B Yip; C H Sherlock; P R Harrigan; M V O'Shaughnessy; J S Montaner Journal: J Infect Dis Date: 1999-10 Impact factor: 5.226
Authors: Christopher D Pilcher; Susan A Fiscus; Trang Q Nguyen; Evelyn Foust; Leslie Wolf; Del Williams; Rhonda Ashby; Judy Owen O'Dowd; J Todd McPherson; Brandt Stalzer; Lisa Hightow; William C Miller; Joseph J Eron; Myron S Cohen; Peter A Leone Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Juan Macias; José C Palomares; José A Mira; María J Torres; José A García-García; José M Rodríquez; Salvador Vergera; Juan A Pineda Journal: J Infect Date: 2005-01-12 Impact factor: 6.072
Authors: T R Dinesha; J Boobalan; S Sivamalar; D Subashini; S S Solomon; K G Murugavel; P Balakrishnan; D M Smith; S Saravanan Journal: J Viral Hepat Date: 2018-02-19 Impact factor: 3.728
Authors: Myres W Tilghman; Don Diego Guerena; Alexei Licea; Josué Pérez-Santiago; Douglas D Richman; Susanne May; Davey M Smith Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Bhavna H Chohan; Kenneth Tapia; Michele Merkel; Arphaxad C Kariuki; Brian Khasimwa; Agatha Olago; Richard Gichohi; Elizabeth M Obimbo; Dalton C Wamalwa Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Davey M Smith; Susanne J May; Josué Pérez-Santiago; Matthew C Strain; Caroline C Ignacio; Richard H Haubrich; Douglas D Richman; Constance A Benson; Susan J Little Journal: AIDS Date: 2009-10-23 Impact factor: 4.177